Preclinical models provide scientific justification and translational relevance for moving novel therapeutics into clinical trials for pediatric cancer

Cancer Research

Volumn 75, Issue 24, 2015, Pages 5176-5186

  Langenau, David M ^a,b   Sweet Cordero, Alejandro ^c   Wechsler Reya, Robert J ^d   Dyer, Michael A ^e,f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD STEM CELL INSTITUTE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BURNHAM INSTITUTE   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ALK GENE; ARF GENE; ATRX GENE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL HETEROGENEITY; CHILD; CHILDHOOD CANCER; EMBRYONAL RHABDOMYOSARCOMA; EWING SARCOMA; GENE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETICALLY ENGINEERED MOUSE STRAIN; GLIOMA; HUMAN; NEUROBLASTOMA; NONHUMAN; ONCOGENE RAS; PARP1 GENE; PDGFRA GENE; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW; RHABDOMYOSARCOMA; SLNF11 GENE; TRANSLATIONAL RESEARCH; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ZEBRA FISH; ANIMAL; DISEASE MODEL; NEOPLASMS; ONCOLOGY; PEDIATRICS; PROCEDURES;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PEDIATRICS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84955254840     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1308     Document Type: Review

References (75)

1. Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL. Declining childhood and adolescent cancer mortality. Cancer 2014; 120: 2497-506.
2. Brennan R, Federico S, Dyer MA. The war on cancer: Have we won the battle but lost the war? Oncotarget 2010; 1: 77-83.
3. Downing JR, Wilson RK, Zhang J, Mardis ER, Pui CH, Ding L, et al. The pediatric cancer genome project. Nat Genet 2012; 44: 619-22.
4. Chen X, Pappo A, Dyer MA. Pediatric solid tumor genomics and developmental pliancy. Oncogene 2015; 34: 5207-15.
5. Hobin JA, Deschamps AM, Bockman R, Cohen S, Dechow P, Eng C, et al. Engaging basic scientists in translational research: Identifying opportunities, overcoming obstacles. J Transl Med 2012; 10: 72.
6. Hobin JA, Galbraith RA. Engaging basic scientists in translational research. Faseb J 2012; 26: 2227-30.
7. Chen X, Bahrami A, Pappo A, Easton J,Dalton J,Hedlund E, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep 2014; 7: 104-12.
8. Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 2013; 24: 710-24.
9. Langenau DM, Traver D, Ferrando AA, Kutok JL, Aster JC, Kanki JP, et al. Myc-induced T cell leukemia in transgenic zebrafish. Science 2003; 299: 887-90.
10. Chen J, Jette C, Kanki JP, Aster JC, Look AT, Griffin JD.NOTCH1-induced Tcell leukemia in transgenic zebrafish. Leukemia 2007; 21: 462-71.
11. Langenau DM, Zon LI. The zebrafish: A new model of T-cell and thymic development. Nat Rev Immunol 2005; 5: 307-17.
12. Sabaawy HE, Azuma M, Embree LJ, Tsai HJ, Starost MF,Hickstein DD. TELAML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2006; 103: 15166-71.
13. Langenau DM, Keefe MD, Storer NY, Guyon JR, Kutok JL, Le X, et al. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 2007; 21: 1382-95.
14. Zhu S, Lee JS, Guo F, Shin J, Perez-Atayde AR, Kutok JL, et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 2012; 21: 362-73.
15. IgnatiusMS, Chen E, Elpek NM,Fuller AZ, Tenente IM, Clagg R, et al. In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Cancer Cell 2012; 21: 680-93.
16. Blackburn JS, Liu S, Wilder JL, Dobrinski KP, Lobbardi R, Moore FE, et al. Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer Cell 2014; 25: 366-78.
17. Le X, Pugach EK, Hettmer S, Storer NY, Liu J, Wills AA, et al. A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development. Development 2013; 140: 2354-64.
18. Ridges S, Heaton WL, Joshi D, Choi H, Eiring A, Batchelor L, et al. Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood 2012; 119: 5621-31.
19. Gutierrez A, Pan L, Groen RW, Baleydier F, Kentsis A, Marineau J, et al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest 2014; 124: 644-55.
20. White RM, Cech J, Ratanasirintrawoot S, Lin CY, Rahl PB, Burke CJ, et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 2011; 471: 518-22.
21. Gutierrez A, Feng H, Stevenson K, Neuberg DS, Calzada O, Zhou Y, et al. Loss of function tp53mutations do not accelerate the onset of myc-induced T-cell acute lymphoblastic leukaemia in the zebrafish. Br J Haematol 2014; 166: 84-90.
22. Blackburn JS, Liu S, Raiser DM, Martinez SA, Feng H, Meeker ND, et al. Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency. Leukemia 2012; 26: 2069-78.
23. Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. NatMed 2014; 20: 1130-7.
24. Konantz M, Balci TB, Hartwig UF, Dellaire G, Andre MC, Berman JN, et al. Zebrafish xenografts as a tool for in vivo studies on human cancer. Ann NY Acad Sci 2012; 1266: 124-37.
25. Smith AC, Raimondi AR, Salthouse CD, Ignatius MS, Blackburn JS, Mizgirev IV, et al. High-throughput cell transplantation establishes that tumorinitiating cells are abundant in zebrafish T-cell acute lymphoblastic leukemia. Blood 2010; 115: 3296-303.
26. Tang Q, Abdelfattah NS, Blackburn JS, Moore JC, Martinez SA, Moore FE, et al.Optimized cell transplantation using adult rag2 mutant zebrafish.Nat Methods 2014; 11: 821-4.
27. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr., Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-21.
28. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature 1992; 359: 295-300.
29. Jonkers J, Berns A. Conditional mouse models of sporadic cancer. Nat Rev Cancer 2002; 2: 251-65.
30. Sharpless NE, Depinho RA. The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006; 5: 741-54.
31. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013; 153: 910-8.
32. Wefers B, Meyer M, Ortiz O, Hrabe de Angelis M, Hansen J, Wurst W, et al. Direct production of mouse disease models by embryo microinjection of TALENs and oligodeoxynucleotides. Proc Natl Acad Sci U S A 2013; 110: 3782-7.
33. Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han YC, et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 2014; 516: 423-7.
34. Sanchez-Rivera FJ, Papagiannakopoulos T, Romero R, Tammela T, Bauer MR, Bhutkar A, et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 2014; 516: 428-31.
35. Haldar M, Randall RL, Capecchi MR. Synovial sarcoma: From genetics to genetic-based animal modeling. Clin Orthop Relat Res 2008; 466: 2156-67.
36. Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR. Alveolar rhabdomyosarcomas in conditional Pax3: Fkhr mice: Cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004; 18: 2614-26.
37. Straessler KM, Jones KB, Hu H, Jin H, van de Rijn M, Capecchi MR. Modeling clear cell sarcomagenesis in the mouse: Cell of origin differentiation state impacts tumor characteristics. Cancer Cell 2013; 23: 215-27.
38. Brennan RC, Federico S, Bradley C, Zhang J, Flores-Otero J, WilsonM, et al. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin- 3a. Cancer Res 2011; 71: 4205-13.
39. Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, et al. Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep 2014; 9: 829-41.
40. Benavente CA, McEvoy JD, Finkelstein D, Wei L, Kang G, Wang YD, et al. Cross-species genomic and epigenomic landscape of retinoblastoma. Oncotarget 2013; 4: 844-59.
41. Ng JM, Curran T. The Hedgehog's tale: Developing strategies for targeting cancer. Nat Rev Cancer 2011; 11: 493-501.
42. Zhao X, Liu Z, Yu L, Zhang Y, Baxter P, Voicu H, et al. Global gene expression profiling confirms the molecular fidelity of primary tumorbased orthotopic xenograft mouse models of medulloblastoma. Neuro Oncol 2012; 14: 574-83.
43. Stewart E, Shelat AS, Bradley C, Chen X, Federico S, Thiagaragan S, et al. Development and Characterization of a Human Orthotopic Neuroblastoma Xenograft. Dev Biol 2015 Apr 9. [Epub ahead of print].
44. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patientderived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012; 9: 338-50.
45. Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 2015; 518: 422-6.
46. Lee DF, Su J, Kim HS, Chang B, Papatsenko D, Zhao R, et al. Modeling familial cancer with induced pluripotent stem cells. Cell 2015; 161: 240-54.
47. Funato K, Major T, Lewis PW, Allis CD, Tabar V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science 2014; 346: 1529-33.
48. Lussier DM, Johnson JL, Hingorani P, Blattman JN. Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer 2015; 3: 21.
49. Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015; 520: 692-6.
50. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189-99.
51. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-71.
52. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515: 577-81.
53. Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 2014; 32: 364-72.
54. Morton CL, Iacono L, Hyatt JL, Taylor KR, Cheshire PJ, Houghton PJ, et al. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother Pharmacol 2005; 56: 629-36.
55. Morton CL, Wierdl M, Oliver L, Ma MK, Danks MK, Stewart CF, et al. Activation of CPT-11 in mice: Identification and analysis of a highly effective plasma esterase. Cancer Res 2000; 60: 4206-10.
56. Zhang J, Benavente C, McEvoy J, Flores-Otero J, Ding L, Chen X, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012; 481: 329-34.
57. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363: 1324-34.
58. Bronte V, Murray PJ. Understanding local macrophage phenotypes in disease: Modulating macrophage function to treat cancer. Nat Med 2015; 21: 117-9.
59. Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012; 481: 329-34.
60. McEvoy J, Flores-Otero J, Zhang J, Nemeth K, Brennan R, Bradley C, et al. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell 2011; 20: 260-75.
61. Rodriguez-Galindo C, Wilson MW, Haik BG, Merchant TE, Billups CA, Shah N, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 2003; 21: 2019-25.
62. Stewart E, Federico S, Karlstrom A, Shelat A, Sablauer A, Pappo A, et al. The childhood solid tumor network: A new resource for the developmental biology and oncology research Communities. Dev Biol 2015. Jun 9. [Epub ahead of print].
63. Zhang F, Tagen M, Throm S, Mallari J, Miller L, Guy RK, et al. Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos 2011; 39: 15-21.
64. Voon HP, Hughes JR, Rode C, De La Rosa-Velazquez IA, Jenuwein T, Feil R, et al. ATRX plays a key role in maintaining silencing at interstitial heterochromatic loci and imprinted genes. Cell Rep 2015; 11: 405-18.
65. Flynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, Ganem NJ, et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 2015; 347: 273-7.
66. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012; 307: 1062-71.
67. Cheung NK, Dyer MA. Neuroblastoma: Developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013; 13: 397-411.
68. Devoto M, Specchia C, Laudenslager M, Longo L, Hakonarson H, Maris J, et al. Genome-wide linkage analysis to identify genetic modifiers of ALK mutation penetrance in familial neuroblastoma. Hum Hered 2011; 71: 135-9.
69. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-5.
70. Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, et al. The ALK (F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 2012; 22: 117-30.
71. Carpenter EL, Mosse YP. Targeting ALK in neuroblastoma-preclinical and clinical advancements. Nat Rev Clin Oncol 2012; 9: 391-9.
72. Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, De Wilde B, et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci Transl Med 2012; 4: 141ra91.
73. Schulte JH, Lindner S, Bohrer A, Maurer J, De Preter K, Lefever S, et al. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene 2013; 32: 1059-65.
74. Mosse YP, LimMS, Voss SD, Wilner K, Ruffner K, Laliberte J, et al. Safety and activity of crizotinib for paediatric patientswith refractory solid tumours or anaplastic large-cell lymphoma: A Children's Oncology Group phase 1 consortium study. Lancet Oncol 2013; 14: 472-80.
75. Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 2014; 26: 682-94.